Seeking strategic partners for a next-generation digital biomarker detection platform based on individual nanoparticle counting. The technology enables ultra-sensitive, multiplexed quantification of low-abundance proteins and nucleic acids, with applications in early detection, patient stratification and disease monitoring across major diagnostic markets. Partnership opportunities include RUO applications, clinical validation, co-development, licensing and commercialization.
